Challenges in Parkinson's disease: Restoration of the nigrostriatal dopamine system is not enough

Lancet Neurology

Volumn 3, Issue 5, 2004, Pages 309-316

  Lang, Anthony E ^a   Obeso, Jose A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; AMANTADINE; ANTIHISTAMINIC AGENT; APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; CANNABINOID RECEPTOR ANTAGONIST; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; ENTACAPONE; ETIRACETAM; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; LISURIDE; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE ANTAGONIST; PIRIBEDIL; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TOPIRAMATE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; CLINICAL RESEARCH; DISEASE COURSE; DOPAMINERGIC SYSTEM; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; NIDATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUBSTANTIA NIGRA;

EID: 1942520420     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(04)00740-9     Document Type: Note

References (83)

1. Holden C. Versatile cells against intractable disease. Science. 297:2002;500-502.
2. Lindvall O. Update on fetal transplantation: the Swedish experience. Mov Disord. 13:1998;83-87.
3. Freeman T.B. From transplants to gene therapy for Parkinson's disease. Exp Neurol. 144:1997;47-50.
4. Kordower J.H., Goetz C.G., Freeman T.B., Olanow C.W. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol. 144:1997;41-46.
5. Toledo-Aral J.J., Méndez-Ferrer S., Pardal R., López-Barneo J. Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson's disease. Brain Res Bull. 57:2002;847-853.
6. Watts R.L., Stover N.P., Cornfeldt M.L., Scheikert A.W., Allen R.C., Bakay R.E. Stereotaxic intrastriatal implantation of retinal pigment epithelial cells attached to gelatin microcarriers: a 12-month open-label trial in 6 advanced Parkinson's disease (PD) patients. Mov Disord. 17:(suppl 5):2002;S107.
7. Schumacher J.M., Ellias S.A., Palmer E.P., et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology. 54:2000;1042-1050.
8. Björklund L.M., Sánchez-Pernaute R., Chung S.M., et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA. 99:2002;2344-2349.
9. Kim J.H., Auerbach J.M., Rodríguez-Gómez J.A., et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 418:2002;50-56.
10. Freese A., Stern M., Kaplitt M.G., et al. Prospects for gene therapy in Parkinson's disease. Mov Disord. 11:1996;469-488.
11. Kang U.J. Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. Mov Disord. 13:1998;59-72.
12. Siegel G.J., Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Rev. 33:2000;199-227.
13. Palfi S., Leventhal L., Chu Y.P., et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 22:2002;4942-4954.
14. Marsden C.D., Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1:1976;292-296.
15. Muenter M.D., Tyce G.M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 46:1971;231-239.
16. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 16:2001;448-458.
17. Lang A.E., Lozano A.M. Parkinson's disease: first of two parts. N Engl J Med. 339:1998;1044-1053.
18. Lang A.E., Lozano A.M. Parkinson's disease: second of two parts. N Engl J Med. 339:1998;1130-1143.
19. Tandberg E., Larsen J.P., Aarsland D., Cummings J.L. The occurrence of depression in Parkinson's disease: a community-based study. Arch Neurol. 53:1996;175-179.
20. Hobson D.E., Lang A.E., Martin W.R.W., Razmy A., Rivest J., Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 287:2002;455-463.
21. Ondo W.G., Vuong K.D., Khan H., Atassi F., Kwak C., Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 57:2001;1392-1396.
22. Aarsland D., Andersen K., Larsen J.P., Lolk A., Nielsen H., Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 56:2001;730-736.
23. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci. 20:1973;415-455.
24. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med. 318:1988;876-880.
25. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 59:1995;597-600.
26. Bezard E., Dovero S., Prunier C., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci. 21:2001;6853-6861.
27. Spillantini M.G., Schmidt M.L., Lee V.M.Y., Jakes R., Goedert M. α-Synuclein in Lewy bodies. Nature. 388:1997;839-840.
28. Braak H., Sandmann-Keil D., Gai W.P., Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry. Neurosci Lett. 265:1999;67-69.
29. Agid Y., Javoy F., Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol. 245:1973;150-151.
30. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1990;290-296.
31. Javoy-Agid F., Ruberg M., Taquet H., et al. Biochemical neuroanatomy of the human substantia nigra (pars compacta) in normal and Parkinsonian subjects. Adv Neurol. 35:1982;151-163.
32. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv Neurol. 45:1987;19-34.
33. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 119:1996;585-591.
34. 123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 57:2001;2089-2094.
35. Obeso J.A., Rodríguez-Oroz M.C., Rodríguez M., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23:2000;S8-19.
36. Vila M., Périer C., Féger J., et al. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur J Neurosci. 12:2000;337-344.
37. Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., Brotchie J.M. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6- tetrahydropyridine monkeys. Neurobiol Dis. 8:2001;343-350.
38. Herrero M.T., Levy R., Ruberg M., et al. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease. Adv Neurol. 69:1996;209-216.
39. Bezard E., Dovero S., Prunier C., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci. 21:2001;6853-6861.
40. Hirsch E.C., Orieux G., Muriel M.P., Francois C., Feger J. Nondopaminergic neurons in Parkinson's disease. Adv Neurol. 91:2003;29-37.
41. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., Brotchie J.M. Enhanced levels of endogenous cannabinoids in the glob us pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14:2000;1432-1438.
42. Whone A.L., Moore R.Y., Piccini P.P., Brooks D.J. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol. 53:2003;206-213.
43. Prensa L., Cossette M., Parent A. Dopaminergic innervation of human basal ganglia. J Chem Neuroanat. 20:2000;207-213.
44. Blandini F., Porter R.H.P., Greenamyre J.T. Glutamate and Parkinson's disease. Mol Neurobiol. 12:1996;73-94.
45. Rodriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 44:1998;S175-S188.
46. Piallat B., Benazzouz A., Benabid A.L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci. 8:1996;1408-1414.
47. Nakao N., Nakai E., Nakai K., Itakura T. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann Neurol. 45:1999;640-651.
48. Luo J., Kaplitt M.G., Fitzsimons H.L., et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science. 298:2002;425-429.
49. Takada M., Matsumura M., Kojima J., et al. Protection against dopaminergic nigrostriatal cell death by excitatory input ablation. Eur J Neurosci. 12:2000;1771-1780.
50. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci. 22:1999;123-144.
51. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord. 13:1998;24-34.
52. Foley P., Riederer P. Pathogenesis and preclinical course of Parkinson's disease. J Neural Trans. 56:1999;31-74.
53. Mark M.H., Dickson D.W., Sage J.I., Duvoisin R.C. The clinicopathologic spectrum of Lewy body disease. Adv Neurol. 69:1996;315-318.
54. Del Tredici K., Rüb U., De Vos R.A.I., Bohl J.R.E., Braak H. Where does Parkinson disease pathology begin in the brain? J Neuro Pathol Exp Neurol. 61:2002;413-426.
55. Braak H., Del Tredici K., Rüb U., De Vos R.A.I., Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 24:2003;197-211.
56. Hawkes C.H., Shephard B.C., Daniel S.E. Is Parkinson's disease a primary olfactory disorder? Q J Med. 92:1999;473-480.
57. Agid Y., Javoy-Agid F., Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. Marsden C.D., Fahn S. Movement disorders 2. 1987;166-230 Butterworths, London.
58. Harding A.J., Broe G.A., Halliday G.M. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 125:2002;391-403.
59. Harding A.J., Stimson E., Henderson J.M., Halliday G.M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain. 125:2002;2431-2445.
60. Braak H., Braak E., Yilmazer D., Schultz C., De Vos R.A.I., Jansen ENH. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 46:1995;15-31.
61. Braak H., Rüb U., Sandmann-Keil D., et al. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol (Berl). 99:2000;489-495.
62. Braak H., Braak E., Yilmazer D., et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl). 88:1994;493-500.
63. Henderson J.M., Carpenter K., Cartwright H., Halliday G.M. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain. 123:2000;1410-1421.
64. Rüb U., Del Tredici K., Schultz C., et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by a-synuclein immunopositive inclusion body pathology. Neurobiol Aging. 23:2002;245-254.
65. Hurtig H.I., Trojanowski J.Q., Galvin J., et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 54:2000;1916-1921.
66. Jellinger K.A. Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Trans. 59:2000;185-212.
67. Pearce R.K.B., Hawkes C.H., Daniel S.E. The anterior olfactory nucleus in Parkinson's disease. Mov Disord. 10:1995;283-287.
68. Bjorklund A., Dunnett S.B., Brundin P., et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2:2003;437-445.
69. Dunnett S.B., Bjorklund A., Lindvall O. Cell therapy in Parkinson's disease: stop or go? Nat Rev Neurosci. 2:2001;365-369.
70. Lindvall O. Neural transplantation: a hope for patients with Parkinson's disease. Neuroreport. 8:1997;iii-x.
71. Piccini P., Brooks D.J., Björklund A., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci. 2:1999;1137-1140.
72. Nakamura T., Dhawan V., Chaly T., et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol. 50:2001;181-187.
73. Kordower J.H., Freeman T.B., Snow B.J., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med. 332:1995;1118-1124.
74. Kordower J.H., Freeman T.B., Chen E.Y., et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord. 13:1998;383-393.
75. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 344:2001;710-719.
76. Olanow C.W., Goetz C.G., Kordower J.H., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 54:2003;403-414.
77. Greene P.E., Fahn S., Tsai W.Y., et al. Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. Mov Disord. 14:1999;904.
78. Hagell P., Piccini P., Björklund A., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci. 5:2002;627-628.
79. Arenas E. Stem cells in the treatment of Parkinson's disease. Brain Res Bull. 57:2002;795-808.
80. Hauser R.A., Watts R.L., Freeman T.B., et al. A double-blind randomized controlled, multi-center clinical trial of the safety and efficacy of transplanted fetal procine ventral mesencephalic cells versus imitation surgery in patients with PD. Mov Disord. 16:2001;983-984.
81. Gill S.S., Patel N.K., Hotton G.R., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 9:2003;589-595.
82. Kang U.J. Gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. Mov Disord. 13:(suppl 1):1998;59-72.
83. Mendez I., Dagher A., Hong M., et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study-report of three cases. J Neurosurg. 96:2002;589-596.